Sequenom Increases Expected Billings for MaterniT21 Plus to 40,000 in 2012 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today raised its estimates for the number of billed MateriT21 Plus tests for 2012 to 40,000 as adoption of the test accelerated during the first quarter.

The San Diego-based firm had previously forecast 25,000 billings for the non-invasive fetal aneuploidy test for the year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genome sequencing study of Yakutian horses, tardigrade genome, and more.

A guest post at Retraction Watch discusses what funders can do to improve research reproducibility.

Researchers report in Nature this week that farming led to genomic adaptations in humans.

The FDA argues that it needs to evaluate the safety and efficacy of laboratory-developed tests, a proposal that divides Republicans.